Pelthos Therapeutics Inc.(PTHS)Earnings, Financials & Key Ratios

PTHS•NYSE

$24.60

Price updated Jul 7, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryCommercial Specialty Pharma

AboutPelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.Show more

Revenue$17M
EBITDA-$30M-319.5%
Net Income-$43M-444.5%
EPS (Diluted)-23.04-70.2%
Gross Margin62.65%
EBITDA Margin-179.05%
Operating Margin-193.09%
Net Margin-257.93%
ROE-239.55%

PTHS Price & Volume

Pelthos Therapeutics Inc. (PTHS) stock price & volume — 10-year historical chart

Loading chart...

Aggressive Commercial Scaling Pressures Liquidity Position

Investment Thesis • Updated 2026Q1

VerdictNegative

Growth:Expanding

Profitability:Negative

Financial:Vulnerable

Cash Flow:Burning

Primary Risk:Insufficient liquidity for commercialization

Key Thesis Takeaways

Pelthos Therapeutics is currently navigating a high-stakes commercial transition for its ZELSUVMI platform, evidenced by a rapid revenue ramp to $10.9 million in 2026Q1.
However, the company's reliance on aggressive SG&A spending, which reached $20.6 million in the same period, creates a significant risk of continued dilution for shareholders.
Investors should monitor whether the firm can achieve operational scale before its $52.9 million debt load and persistent cash burn necessitate further capital market intervention.

Verdict Logic

the company's precarious financial position, characterized by a $10.2 million net loss in 2026Q1 and a $52.9 million debt load, suggests substantial execution risk that outweighs current revenue growth.

PTHS Growth Metrics

Pelthos Therapeutics Inc. (PTHS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years-

3 Years-

TTM-

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM-600.88%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM-228.15%

Return on Capital

10 Years-63.78%

5 Years-63.78%

3 Years-63.78%

Last Year-63.78%

Latest PTHS News

Recent stock market news and headlines for Pelthos Therapeutics Inc. (PTHS)

GlobeNewsWire·Jun 30, 2026

Pelthos Therapeutics Added to Russell 3000E™ Growth Benchmark, Russell Microcap® and Russell Microcap® Growth Benchmark Indexes

DURHAM, N.C., June 30, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs, (“Pelthos”), today announced that the company was added as a member of the Russell 3000E™ Growth Benchmark, Russell Microcap®, and Russell Microcap® Growth Benchmark Indexes effective when the US market opened on June 29 as part of the 2026 Russell indexes reconstitution.

Peers Comparison

Key metrics vs top competitors for Pelthos Therapeutics Inc. (PTHS)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
PTHSPelthos Therapeutics Inc.Current	$24.60	$81.47M	-1.07	—	-257.93%	-239.55%	—
COLLCollegium Pharmaceutical, Inc.	$36.44	$1.18B	21.06	23.62%	9.41%	26.74%	—
AVDLAvadel Pharmaceuticals plc	$21.64	$2.1B	-42.43	504.79%	-0.11%	-0.33%	—
SUPNSupernus Pharmaceuticals, Inc.	$47.41	$2.73B	-69.72	8.63%	-3.74%	-2.73%	—
LNTHLantheus Holdings, Inc.	$103.41	$6.73B	30.33	0.5%	18.05%	24.33%	—
PRAXPraxis Precision Medicines, Inc.	$323.95	$9.36B	-24.03	-100%	—	-43.02%	—

Compare PTHS vs Peers

Pelthos Therapeutics Inc. (PTHS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs COLL

Most directly comparable listed peer for PTHS.

Scale Benchmark

vs MCK

Larger-name benchmark to compare PTHS against a more recognizable public peer.

Peer Set

Compare Top 5

vs COLL, AVDL, SUPN, LNTH

Get notified when PTHS posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

PTHS Frequently Asked Questions

Pelthos Therapeutics Inc. (PTHS) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

What is Pelthos Therapeutics Inc.'s revenue?

Pelthos Therapeutics Inc. (PTHS) reported $27.7M in revenue for fiscal year 2025.

Is PTHS profitable?

Pelthos Therapeutics Inc. (PTHS) reported a net loss of $51.6M for fiscal year 2025.

Dividend & Returns

What is PTHS's return on equity?

Pelthos Therapeutics Inc. (PTHS) has a return on equity (ROE) of -239.6%. Negative ROE indicates the company is unprofitable.

What is Pelthos Therapeutics Inc.'s free cash flow?

Pelthos Therapeutics Inc. (PTHS) had negative free cash flow of $35.4M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in PTHS back in 2022?

Total return calculator · dividends reinvested · 4+ years of data

See returns →

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

PTHSPelthos Therapeutics Inc.Current

$24.60

$81.47M

-1.07

—

-257.93%

-239.55%

—

COLLCollegium Pharmaceutical, Inc.

$36.44

$1.18B

21.06

23.62%

9.41%

26.74%

—

AVDLAvadel Pharmaceuticals plc

$21.64

$2.1B

-42.43

504.79%

-0.11%

-0.33%

—

SUPNSupernus Pharmaceuticals, Inc.

$47.41

$2.73B

-69.72

8.63%

-3.74%

-2.73%

—

LNTHLantheus Holdings, Inc.

$103.41

$6.73B

30.33

0.5%

18.05%

24.33%

—

PRAXPraxis Precision Medicines, Inc.

$323.95

$9.36B

-24.03

-100%

—

-43.02%

—